X


See our webpage about the GA-map® product platform

 

Visit page
Skip to content
Genetic Analysis
Genetic Analysis
  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
    • Subscriptions
  • Contact us
Genetic Analysis
  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
    • Subscriptions
  • Contact us

Press Releases

Genetic Analysis announces proposed changes to the Board

2025-05-052025-05-05

Genetic Analysis announces placement of a directed share issue of NOK 12.8 million

2025-05-052025-05-05

Genetic Analysis AS publishes Annual Report 2024

2025-05-052025-05-02

Genetic Analysis AS and Thalys Medical Technology Group are pleased to announce the launch of a microbiome test to the Chinese Consumer Health market

2025-04-222025-04-22

Genetic Analysis AS publishes year-end report 2024

2025-02-262025-02-26

Genetic Analysis and Ferring Pharmaceuticals Announce A Collaboration To Develop A New Microbiome Rapid Diagnostic Test

2024-12-262024-12-20

Genetic Analysis AS: Mandatory notification of trade – Primary Insiders

2024-11-25

Publication of Q3 Interim Report January – September 2024

2024-11-162024-11-15

Publication of Half-year report 2024

2024-08-30

Genetic Analysis AS launches the GA-map® Discovery reagent kit – a precision microbiome research assay

2024-11-142024-08-15
Post navigation
Older posts
Page1 Page2 … Page12 Next →

Genetic Analysis AS is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Contact

Phone: +47 48 32 16 10
E-mail: info@genetic-analysis.com
Address: Genetic Analysis AS, Ulvenveien 80B
0581 Oslo, Norway

Open Google Maps
Connect

LinkedIn

Facebook

Twitter

Navigate

Contact Us

Terms of Use

Privacy Policy

© 2023 Genetic Analysis

  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
    • Subscriptions
  • Contact us